The first agents in the family of PD-1/PD-L1 inhibitors to be approved by the Food and Drug Administration (FDA) were the humanized monoclonal IgG4 antibodies, pembrolizumab and nivolumab, that targeted PD-1 in unresectable or advanced melanoma [3–10]. Here, PDCD1 is linked to melanoma.